Viral Hepatitis Education- We do community viral hepatitis education for injecting drug users, community through our Neddle and Syringe Program with funding from Global Fund from New Funding Model Fund to Optimising investment for HIV Fund. We also do case finding, refer, and linkages to treatment for LGBTQ, and sex-workers communities.
Immunization programs: We collaborate with the Government for mobilization for routine immunizations against hepatitis B to infants and children. We also support hepatitis B vaccinations to hard-to-reach populations and most at-risk young people.
Advocacy for Hepatitis Budgetary Allocation at the Government Level – We are currently advocating for budgetary allocation for Hepatitis prevention at the State level Government. Currently, TB, HIV, Malaria, and Family Planning have the budgetary allocation yearly for project implementation but Hepatitis does not have and we are implementing an Advocacy strategy to get budgetary allocation at the State level.
World Community Advisory Board (CAB) on Hepatitis C Generics and Diagnostics – We are also part of the World Community Advisory Board (CAB) on Hepatitis C Generic AND Diagnostics to demand equitable access to treatment for hepatitis C virus (HCV) from multinational pharmaceutical companies.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close
